291.77MMarket Cap-8.80P/E (TTM)
2.7900High2.6600Low205.44KVolume2.6600Open2.6800Pre Close563.72KTurnover0.25%Turnover RatioLossP/E (Static)105.91MShares4.620052wk High11.20P/B226.13MFloat Cap1.610052wk Low--Dividend TTM82.08MShs Float27.6000Historical High--Div YieldTTM4.85%Amplitude0.5300Historical Low2.7430Avg Price1Lot Size
ProQR Therapeutics Stock Forum
Singapore, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Webuy Global Ltd. (NASDAQ:WBUY) ("Webuy" or the "Company"), a Southeast Asian community e-commerce innovator, is thrilled to announce the launch of its cutting-edge Travel AI, Micky1.0. This tool, available through WhatsApp, helps simplify travel planning and provides personalized support whenever and wherever it is needed.
With just a WhatsApp number, users can interact with Micky1.0 to get immediate answers to the...
ProQR Therapeutics Announces $8.1 Million in New Funding From Rett Syndrome Research Trust to Expand Rna Editing Collaboration
📊⚡️📊
big offering watchout
NEWS
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical data for its AX-0810 pipelin...
No comment yet